Gilead Sciences, Inc. (NASDAQ:GILD)

Stock Price: $62.63

+0.29 (0.46%)

Updated Sep 27, 2022 08:00 PM GMT+0000

Featured app

Invest now

68% of retail CFD accounts lose money

Overview

Financials

Statistics

Profile

Chart

Market Cap	78.50B
Revenue	27.52B
Gross Profit	20.80B
Shares Out	1.25B
EPS (ttm)	3.28
PE Ratio	18.8869
Forward PE	9.3823
Dividend Rate (ttm)	2.8494
Dividend Yield	0.0457

Trading Day	Sep 27
Last Price	$62.63
Previous Close	$62.34
Change ($)	0.29
Change (%)	0.46%
Day's Open	62.43
Day's Range	62.28 - 63.52
Day's Volume	7.13M
52 Week Range	55.27 - 71.47

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world.

In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

NASDAQ:GILD stock is currently trading at $62.63 as of 08:00 PM UTC, Sep 27, 2022. Use the financials tab to find out more about Gilead Sciences, Inc.'s key financial metrics and recent earnings reports, or track its share price in real time on the chart tab. If you would like to buy shares in Gilead Sciences, Inc., our detailed guide explains how to buy Gilead Sciences, Inc. stock.

News

Mizuho: these two biotech stocks are worth buying right now May 9, 2022

Should I buy Gilead Sciences shares in May 2022? May 2, 2022

Should I buy Gilead Sciences shares after strong Q4 results? February 5, 2022

Should you invest in Gilead Sciences after guiding FY2021 earnings above estimates? October 28, 2021

4 key takeaways from Gilead Sciences Q1 earnings report April 30, 2021

Gilead Sciences says Veklury sales made up 25% of the total Q4 revenue February 5, 2021

Gilead Sciences shares rise as Morgan Stanley upgrades its price target to $83 January 22, 2021

Gilead Sciences values its sales at £4.31 billion in the fiscal third quarter October 28, 2020

Gilead Sciences to buy Immunomedics Inc for £16.32 billion September 14, 2020

Gilead CEO talks remdesivir pricing June 29, 2020

Quick info

Country

United States

Industry

Biological Product (except Diagnostic) Manufacturing

Sector

Manufacturing

Employees

13,600

CEO

Daniel O'Day

Address

333 Lakeside Dr
Foster City
California
94404-1147

Phone

16505743000

Website

www.gilead.com

Ticker Symbol

GILD

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

Gilead Sciences, Inc. income statements (2022) (USD)

	August 2022
Total Revenue	6.26B
Cost of Revenue	1.44B
Gross Profit	4.82B
Research & Development	1.10B
Selling General & Admin	1.36B
Operating Expense	3.90B
Operating Income	2.36B
Other Income Expense Net	0
EBIT	2.36B
Interest Income	242M
Pretax Income	1.50B
Income Tax	368M
Minority Interest	-9M
Net Income	1.14B
Net Income Basic	1.14B

Gilead Sciences, Inc. income statements (2021) (USD)

	November 2021
Total Revenue	7.42B
Cost of Revenue	1.22B
Gross Profit	6.20B
Research & Development	1.15B
Selling General & Admin	1.19B
Operating Expense	3.56B
Operating Income	3.86B
Other Income Expense Net	0
EBIT	3.86B
Interest Income	250M
Pretax Income	3.44B
Income Tax	852M
Minority Interest	-6M
Net Income	2.59B
Net Income Basic	2.59B

Gilead Sciences, Inc. income statements (2020) (USD)

	November 2020	September 2020	June 2020	March 2020	March 2020
Total Revenue	6.58B	6.58B	5.13B	5.52B	5.52B
Cost of Revenue	1.14B	1.14B	1.06B	0.97B	0.97B
Gross Profit	5.44B	5.44B	4.06B	4.55B	4.55B
Research & Development	1.16B	1.16B	1.30B	1.10B	1.10B
Selling General & Admin	1.11B	1.11B	1.24B	1.08B	1.08B
Operating Expense	3.41B	3.41B	3.60B	3.15B	3.15B
Operating Income	3.17B	3.17B	1.52B	2.38B	2.38B
Other Income Expense Net	0	-2.35B	-4.5B	-372M	-372M
EBIT	3.17B	3.17B	1.52B	2.38B	2.38B
Interest Income	236M	236M	240M	241M	241M
Pretax Income	825M	825M	-2.97B	2B	2B
Income Tax	472M	472M	373M	465M	465M
Minority Interest	-7M	-7M	-7M	-13M	-13M
Net Income	360M	360M	-3.34B	1.55B	1.55B
Net Income Basic	360M	360M	-3.34B	1.55B	1.55B

Gilead Sciences, Inc. income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	5.85B	5.57B	5.65B	5.25B
Cost of Revenue	1.68B	1.04B	1B	0.96B
Gross Profit	4.17B	4.54B	4.65B	4.30B
Research & Development	1.90B	4.99B	1.16B	1.06B
Selling General & Admin	1.20B	1.05B	1.10B	1.03B
Operating Expense	4.79B	7.08B	3.26B	3.04B
Operating Income	1.06B	-1.5B	2.39B	2.21B
Other Income Expense Net	839M	3M	16M	142M
EBIT	1.06B	-1.5B	2.39B	2.21B
Interest Income	243M	250M	248M	254M
Pretax Income	1.90B	-1.5B	2.41B	2.35B
Income Tax	-788M	-333M	535M	382M
Minority Interest	-7M	-3M	-5M	-7M
Net Income	2.70B	-1.17B	1.88B	1.98B
Net Income Basic	2.70B	-1.17B	1.88B	1.98B

Gilead Sciences, Inc. income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	5.78B	5.60B	5.69B	5.14B
Cost of Revenue	1.57B	1.09B	1.20B	1B
Gross Profit	4.21B	4.52B	4.50B	4.14B
Research & Development	1.13B	0.94B	1.19B	0.94B
Selling General & Admin	1.13B	0.95B	0.98B	1B
Operating Expense	3.83B	2.97B	3.37B	2.94B
Operating Income	1.95B	2.63B	2.33B	2.20B
Other Income Expense Net	-0.93B	33M	-239M	-168M
EBIT	1.95B	2.63B	2.33B	2.20B
Interest Income	257M	264M	266M	290M
Pretax Income	1.02B	2.66B	2.09B	2.03B
Income Tax	1.01B	565M	267M	494M
Minority Interest	0	2M	2M	1M
Net Income	3M	2.10B	1.82B	1.54B
Net Income Basic	3M	2.10B	1.82B	1.54B

Gilead Sciences, Inc. income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	5.98B	6.54B	7.13B
Cost of Revenue	1.29B	1.07B	1.16B
Gross Profit	4.69B	5.47B	5.97B
Research & Development	0.98B	789M	864M
Selling General & Admin	1.22B	843M	863M
Operating Expense	3.49B	2.70B	2.89B
Operating Income	2.50B	3.84B	4.24B
Other Income Expense Net	-369M	-167M	-126M
EBIT	2.50B	3.84B	4.24B
Interest Income	297M	291M	269M
Pretax Income	2.13B	3.67B	4.12B
Income Tax	5.96B	0.96B	1.05B
Minority Interest	29M	-6M	-4M
Net Income	-3.87B	2.72B	3.07B
Net Income Basic	-3.87B	2.72B	3.07B

Gilead Sciences, Inc. balance sheet (2022) (USD)

	August 2022
Current Cash	5.66B
Receivables	4.12B
Inventory	1.49B
Current Assets	13.18B
Other Current Assets	1.90B
Short Term Investments	1.90B
Long Term Investments	49.70B
Property/Plant Equipment	5.30B
Good Will	N.A
Intangible Assets	29.89B
Tangible Assets (Net)	-17.96B
Other Assets	4.86B
Total Assets	62.87B
Accounts Payable	565M
Other Current Liabilities	7.63B
Total Current Liabilities	9.22B
Total Liabilities	42.63B
Long Term Debt	25.20B
Current Long Term Debt	1.02B
Minority Interest	-21M
Common Stock	1.26B
Treasury Stock	0
Retained Earnings	15.12B
Capital Surplus	N.A
Shareholder Equity	20.24B
Other Liabilities	N.A

Gilead Sciences, Inc. balance sheet (2021) (USD)

	November 2021
Current Cash	5.74B
Receivables	4.57B
Inventory	1.68B
Current Assets	13.99B
Other Current Assets	2.01B
Short Term Investments	2.01B
Long Term Investments	53.11B
Property/Plant Equipment	5.04B
Good Will	N.A
Intangible Assets	33.90B
Tangible Assets (Net)	-20.76B
Other Assets	3.60B
Total Assets	67.10B
Accounts Payable	585M
Other Current Liabilities	7.15B
Total Current Liabilities	10.25B
Total Liabilities	45.63B
Long Term Debt	25.18B
Current Long Term Debt	2.51B
Minority Interest	1M
Common Stock	1.26B
Treasury Stock	0
Retained Earnings	16.90B
Capital Surplus	N.A
Shareholder Equity	21.47B
Other Liabilities	N.A

Gilead Sciences, Inc. balance sheet (2020) (USD)

	November 2020	September 2020	June 2020	March 2020	March 2020
Current Cash	23.98B	N.A	6.75B	10.05B	10.05B
Receivables	3.91B	3.91B	3.19B	3.91B	3.91B
Inventory	1.01B	1.95B	1.05B	0.99B	0.99B
Current Assets	30.93B	31.92B	24.64B	26.95B	26.95B
Other Current Assets	2.03B	N.A	0.98B	0.97B	0.97B
Short Term Investments	2.03B	N.A	12.62B	10.97B	10.97B
Long Term Investments	29.95B	N.A	5.80B	7.01B	7.01B
Property/Plant Equipment	4.81B	4.81B	4.65B	4.56B	4.56B
Good Will	N.A	N.A	N.A	N.A	N.A
Intangible Assets	12.94B	12.94B	13.23B	13.50B	13.50B
Tangible Assets (Net)	389M	13.35B	-9.47B	-6.12B	-6.12B
Other Assets	6.01B	7.10B	3.50B	3.60B	3.60B
Total Assets	60.88B	60.88B	55.93B	59.74B	59.74B
Accounts Payable	527M	N.A	532M	590M	590M
Other Current Liabilities	7.48B	9.51B	6.12B	5.65B	5.65B
Total Current Liabilities	9.51B	9.51B	10.56B	8.88B	8.88B
Total Liabilities	43.43B	43.41B	37.79B	37.56B	37.56B
Long Term Debt	27.79B	N.A	21.10B	22.10B	22.10B
Current Long Term Debt	1.50B	N.A	3B	2B	2B
Minority Interest	26M	-7M	-7M	-13M	-13M
Common Stock	3.71B	1.25B	1.25B	1.25B	1.25B
Treasury Stock	0	N.A	N.A	N.A	N.A
Retained Earnings	13.71B	N.A	14.45B	18.71B	18.71B
Capital Surplus	N.A	N.A	3.51B	3.31B	3.31B
Shareholder Equity	17.45B	17.47B	18.03B	22.07B	22.07B
Other Liabilities	N.A	N.A	N.A	N.A	N.A

Gilead Sciences, Inc. balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	11.63B	9.47B	11.24B	16.93B
Receivables	3.58B	3.32B	3.40B	3.28B
Inventory	0.92B	882M	884M	898M
Current Assets	30.30B	28.36B	33.73B	34.02B
Other Current Assets	1.12B	1.02B	1.08B	834M
Short Term Investments	13.04B	13.67B	17.13B	12.08B
Long Term Investments	1.66B	4.45B	3.22B	2.39B
Property/Plant Equipment	5.17B	5.04B	4.69B	4.57B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	13.79B	14.86B	15.15B	15.44B
Tangible Assets (Net)	-5.66B	-8.38B	-6.37B	-7.04B
Other Assets	6.60B	2.32B	2.31B	2.30B
Total Assets	61.63B	59.15B	63.21B	62.84B
Accounts Payable	713M	632M	617M	577M
Other Current Liabilities	6.16B	6.34B	6.27B	6.25B
Total Current Liabilities	9.76B	9.57B	8.96B	9.40B
Total Liabilities	38.98B	38.41B	40.46B	40.75B
Long Term Debt	22.72B	22.71B	24.57B	24.51B
Current Long Term Debt	2.50B	2.50B	2B	2.50B
Minority Interest	-7M	-3M	-5M	-7M
Common Stock	1.27B	1.27B	1.27B	1.27B
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	19.39B	17.62B	19.83B	19.33B
Capital Surplus	3.05B	2.87B	2.68B	2.49B
Shareholder Equity	22.53B	20.60B	22.62B	21.95B
Other Liabilities	N.A	N.A	N.A	N.A

Gilead Sciences, Inc. balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	17.94B	14.57B	13.23B	7.64B
Receivables	3.33B	3.47B	3.54B	3.78B
Inventory	814M	816M	859M	885M
Current Assets	35.84B	34.92B	32.73B	30.26B
Other Current Assets	743M	1.34B	1.75B	0.92B
Short Term Investments	13.01B	14.73B	13.35B	17.04B
Long Term Investments	1.57B	2.52B	5.87B	8.23B
Property/Plant Equipment	4.01B	3.79B	3.66B	3.42B
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	15.74B	16.31B	16.50B	16.80B
Tangible Assets (Net)	-7.6B	-6.39B	-7.48B	-8.64B
Other Assets	2.41B	2.65B	2.48B	2.52B
Total Assets	63.68B	64.31B	65.36B	65.38B
Accounts Payable	790M	580M	623M	711M
Other Current Liabilities	6.88B	6.77B	7.27B	7.40B
Total Current Liabilities	10.61B	10.12B	10.91B	10.67B
Total Liabilities	42.14B	41.30B	43.62B	44.73B
Long Term Debt	24.57B	24.57B	26.06B	26.56B
Current Long Term Debt	2.75B	2.75B	3B	2.50B
Minority Interest	0	2M	2M	1M
Common Stock	1.28B	1.29B	1.30B	1.30B
Treasury Stock	N.A	N.A	N.A	N.A
Retained Earnings	19.02B	20.71B	19.83B	19.20B
Capital Surplus	2.28B	2.12B	1.84B	1.56B
Shareholder Equity	21.39B	22.86B	21.67B	20.59B
Other Liabilities	N.A	N.A	N.A	N.A

Gilead Sciences, Inc. balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	7.59B	11.51B	8.71B
Receivables	3.85B	4.12B	4.48B
Inventory	801M	1.14B	1.41B
Current Assets	31.82B	35.32B	28.59B
Other Current Assets	1.03B	0.98B	1.10B
Short Term Investments	18.56B	17.56B	12.90B
Long Term Investments	11.18B	12.97B	15.48B
Property/Plant Equipment	3.30B	3.10B	3.01B
Good Will	N.A	N.A	N.A
Intangible Assets	17.10B	8.34B	8.55B
Tangible Assets (Net)	-8.78B	10.64B	8.47B
Other Assets	2.70B	2.61B	2.32B
Total Assets	70.28B	64.66B	60.26B
Accounts Payable	814M	696M	819M
Other Current Liabilities	7.36B	7.15B	7.67B
Total Current Liabilities	11.64B	9.60B	8.49B
Total Liabilities	49.78B	39.41B	37.17B
Long Term Debt	30.80B	27.52B	26.30B
Current Long Term Debt	2.75B	1.75B	N.A
Minority Interest	29M	-6M	-4M
Common Stock	1.31B	1.31B	1.31B
Treasury Stock	N.A	N.A	N.A
Retained Earnings	19.01B	23.69B	21.82B
Capital Surplus	1.26B	0.91B	733M
Shareholder Equity	20.44B	24.85B	22.68B
Other Liabilities	N.A	N.A	N.A

Gilead Sciences, Inc. cash flow (2022) (USD)

	August 2022
Net Income	1.14B
Depreciation	525M
Changes in Receivables	4.12B
Changes in Inventories	1.49B
Cash Change	5.66B
Cash Flow	1.80B
Capital Expenditures	-143M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-308M
Dividends Paid	N.A
Net Borrowings	18.65B
Other Financing Cash Flows	N.A
Cash Flow Financing	-1B
Exchange Rate Effect	N.A

Gilead Sciences, Inc. cash flow (2021) (USD)

	November 2021
Net Income	2.59B
Depreciation	523M
Changes in Receivables	4.57B
Changes in Inventories	1.68B
Cash Change	5.74B
Cash Flow	3.25B
Capital Expenditures	-139M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-234M
Dividends Paid	N.A
Net Borrowings	19.94B
Other Financing Cash Flows	N.A
Cash Flow Financing	-3.53B
Exchange Rate Effect	N.A

Gilead Sciences, Inc. cash flow (2020) (USD)

	November 2020	September 2020	June 2020	March 2020
Net Income	360M	360M	-3.34B	1.55B
Depreciation	1.05B	N.A	349M	349M
Changes in Receivables	719M	-719M	713M	-325M
Changes in Inventories	-44M	N.A	-37M	15M
Cash Change	5.06B	N.A	-3.31B	-1.58B
Cash Flow	6.25B	N.A	2.57B	1.44B
Capital Expenditures	-469M	N.A	-143M	-171M
Investments	N.A	N.A	-125M	-61M
Investing Activity (other)	N.A	N.A	49M	-112M
Total Investing Cash Flows	-5.64B	N.A	-5.02B	-344M
Dividends Paid	N.A	N.A	-856M	-874M
Net Borrowings	3.29B	N.A	N.A	-500M
Other Financing Cash Flows	N.A	N.A	1M	-86M
Cash Flow Financing	-5.73B	N.A	-874M	-2.61B
Exchange Rate Effect	N.A	N.A	26M	-61M

Gilead Sciences, Inc. cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	2.70B	-1.17B	1.88B	1.98B
Depreciation	350M	347M	348M	359M
Changes in Receivables	-267M	81M	-113M	44M
Changes in Inventories	-60M	-23M	3M	-15M
Cash Change	2.16B	-1.77B	-5.69B	-1.01B
Cash Flow	2.58B	2.90B	2.22B	1.44B
Capital Expenditures	-203M	-200M	-185M	-237M
Investments	840M	2.28B	-5.79B	364M
Investing Activity (other)	-206M	-4.18B	-64M	-238M
Total Investing Cash Flows	431M	-2.1B	-6.04B	-111M
Dividends Paid	-801M	-804M	-800M	-817M
Net Borrowings	N.A	-1.5B	-500M	-750M
Other Financing Cash Flows	-17M	-30M	-7M	-68M
Cash Flow Financing	-896M	-2.52B	-1.86B	-2.37B
Exchange Rate Effect	42M	-55M	-9M	20M

Gilead Sciences, Inc. cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	3M	2.10B	1.82B	1.54B
Depreciation	358M	358M	356M	357M
Changes in Receivables	138M	76M	234M	76M
Changes in Inventories	-119M	-157M	-20M	-14M
Cash Change	3.37B	1.34B	5.59B	55M
Cash Flow	2.35B	2.21B	1.57B	2.27B
Capital Expenditures	-248M	-167M	-297M	-212M
Investments	2.84B	2.23B	5.62B	4.59B
Investing Activity (other)	140M	-38M	-82M	-20M
Total Investing Cash Flows	2.74B	2.03B	5.24B	4.35B
Dividends Paid	-736M	-742M	-740M	-753M
Net Borrowings	N.A	-1.75B	N.A	-4.5B
Other Financing Cash Flows	-22M	-40M	-10M	-414M
Cash Flow Financing	-1.67B	-2.9B	-1.15B	-6.6B
Exchange Rate Effect	-39M	-1M	-71M	26M

Gilead Sciences, Inc. cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	-3.87B	2.72B	3.07B
Depreciation	397M	297M	298M
Changes in Receivables	271M	356M	-444M
Changes in Inventories	-174M	-65M	-9M
Cash Change	-3.92B	2.80B	-1.57B
Cash Flow	2.75B	2.69B	3.53B
Capital Expenditures	-220M	-129M	-123M
Investments	630M	-1.99B	-4.12B
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-10.02B	-2.11B	-4.25B
Dividends Paid	-682M	-682M	-680M
Net Borrowings	4.27B	2.96B	-30M
Other Financing Cash Flows	-189M	-20M	-63M
Cash Flow Financing	3.35B	2.17B	-880M
Exchange Rate Effect	-4M	46M	27M

Gilead Sciences, Inc. dividends (USD)

Ex date	Payment date	Record date	Declared date	Amount	Description	Frequency
14-09-2021	29-09-2021	15-09-2021	N.A	0.71	Ordinary Shares	Quarterly
14-12-2020	30-12-2020	15-12-2020	N.A	0.68	Ordinary Shares	Quarterly
14-09-2020	29-09-2020	15-09-2020	N.A	0.68	Ordinary Shares	Quarterly
11-06-2020	29-06-2020	12-06-2020	N.A	0.68	Ordinary Shares	Quarterly
12-03-2020	29-03-2020	13-03-2020	N.A	0.68	Ordinary Shares	Quarterly
12-12-2019	30-12-2019	13-12-2019	N.A	0.63	Ordinary Shares	Quarterly
11-09-2019	26-09-2019	12-09-2019	N.A	0.63	Ordinary Shares	Quarterly
12-06-2019	26-06-2019	13-06-2019	N.A	0.63	Ordinary Shares	Quarterly
14-03-2019	28-03-2019	15-03-2019	N.A	0.63	Ordinary Shares	Quarterly
13-12-2018	28-12-2018	14-12-2018	N.A	0.57	Ordinary Shares	Quarterly
12-09-2018	26-09-2018	13-09-2018	N.A	0.57	Ordinary Shares	Quarterly
13-06-2018	27-06-2018	14-06-2018	N.A	0.57	Ordinary Shares	Quarterly
15-03-2018	28-03-2018	16-03-2018	N.A	0.57	Ordinary Shares	Quarterly
14-12-2017	28-12-2017	15-12-2017	N.A	0.52	Ordinary Shares	Quarterly
13-09-2017	27-09-2017	14-09-2017	N.A	0.52	Ordinary Shares	Quarterly
13-06-2017	28-06-2017	15-06-2017	N.A	0.52	Ordinary Shares	Quarterly
14-03-2017	29-03-2017	16-03-2017	N.A	0.52	Ordinary Shares	Quarterly
13-12-2016	29-12-2016	15-12-2016	N.A	0.47	Ordinary Shares	Quarterly
13-09-2016	28-09-2016	15-09-2016	N.A	0.47	Ordinary Shares	Quarterly
13-06-2016	28-06-2016	15-06-2016	N.A	0.47	Ordinary Shares	Quarterly
14-03-2016	29-03-2016	16-03-2016	N.A	0.43	Ordinary Shares	Quarterly
14-12-2015	30-12-2015	16-12-2015	N.A	0.43	Ordinary Shares	Quarterly
13-09-2015	28-09-2015	15-09-2015	N.A	0.43	Ordinary Shares	Quarterly
11-06-2015	28-06-2015	15-06-2015	N.A	0.43	Ordinary Shares	Quarterly